Clinical trial
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
NCT00036023 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00036023 |
|---|---|
| Title | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies |
| Official title | A Randomized, Open-Label, Dose-Timing Study of Darbepoetin Alfa Administered Once Every 3 Weeks (Q3W) by Subcutaneous (SC) Injection for Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | darbepoetin alfa |
| First posted | May 8, 2002 |
| Last update posted | May 11, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: